There already is a patent, and it’s owned by Professors Coates and Greenwood.
The patent is titled “
Cell Population Seeding in Dermal Matrices for Endocrine Disorder Management.” The patent was granted in the United States in 2020.
Cell therapy is an area of interest for multiple companies, including large pharma such as Amgen, Vertex, Sanofi and Bayer (BlueRock).
From a regulatory perspective, the
leading nation is Japan.
In 2013, Japan introduced a system through which regenerative-medicine products could be conditionally approved if they are shown to have no major safety issues and are likely to be efficacious.
Large players in cell therapies in Japan include Takeda, Astellas, Sumitomo and SanBio.
(20min delay)